Additionally, we conducted a review of previously reported cases of NUS1 pathogenic/likely pathogenic variants associated with PME to better characterize the clinical and paraclinical features and to explore potential management strategies. This evidence concerns the gene NUS1 and Progressive myoclonic epilepsy.